Intrinsiqq
European Medical Solutions S.A. logo

European Medical Solutions S.A. Quality Score

ALEMS.XBRU

Compare
Quality76

Growth remains strong (avg 100/100), but business quality is pulling the composite down (avg 55/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
100/100
8.0x

Under 20x, reasonable relative to earnings

Cash Flow Multiple
100/100
5.9x

Under 20x cash flow, well covered

Revenue Growth
100/100
12.3%

Above 10% CAGR, strong compounder

Cash Flow Growth
60/100
Just turned +

Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful

Business Quality & Capital Allocation

Share Dilution
80/100
-1.3%

Roughly flat, no meaningful dilution

Margin Trend
100/100
+10.0pp

Expanded 3+pp, strong improvement

Capital Structure
0/100
€13M

Net debt/FCF of 5.3x, high leverage

2022
€5.00M
€15.0M
2023
€5.00M
€19.0M
2024
€5.00M
€21.0M
2025
€6.00M
€19.0M
CashDebt
Return on Capital
40/100
8.3%

8–10%, clearing the bar

Customize WeightsPremiumUpgrade

European Medical Solutions (ALEMS.XBRU) quality: score, margins and returns

European Medical Solutions (ALEMS.XBRU) scores 76/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 7 metrics each scored 0 to 100, on 5.4% operating margins and 8.3% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is European Medical Solutions (ALEMS.XBRU) a high-quality business?+

European Medical Solutions scores 76 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 5.4% operating margin and a 8.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does European Medical Solutions's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from ALEMS.XBRU's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where European Medical Solutions scores well and where it falls behind.

What is European Medical Solutions's return on invested capital (ROIC)?+

European Medical Solutions earns about 8.3% on its invested capital, which is modest. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to ALEMS.XBRU's margins and growth on this scorecard to judge durability.

How profitable is European Medical Solutions?+

European Medical Solutions runs an operating margin of about 5.4% and a net margin of about 3.7%. Revenue has grown at roughly 8.3% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on ALEMS.XBRU: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with ALEMS.XBRU

CompareIntrinsic value
HYL.XBRUHyloris Pharmaceuticals SA
€4.15-3.49%46
ALDMS.XPARDiagnostic Medical Systems S.A.
€0.89-0.67%30
LIK.XETRLimes Schlosskliniken AG
€580.00-1.69%65
IMCCIM Cannabis Corp.
$0.51+8.52%30
NORDH.XOSLNordhealth AS
€2.34-0.85%48
ENZY.XSTOEnzymatica AB
€0.18-4.59%25
SCIB.XSTOSciBase Holding AB
€0.71-0.56%40
SDOS.XSTOScandiDos AB
€0.01-20.00%25

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ALEMS.XBRU

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.